Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC Allo HSCT for Relapsed Multiple Myeloma
NCT04205240Phase 2Terminated
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM). Started Dec 2020; status: terminated.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04205240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205240.